Trial Profile
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Early breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 24 Sep 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov record.
- 24 Sep 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov record.
- 24 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.